Business
SPECTRAL DIAGNOSTICS TO PRESENT AT BIOFINANCE 2011
May 19, 2011 (Canada NewsWire Group) -- TORONTO, May 19 /CNW/ - Spectral Diagnostics Inc., (...
About this update from Spectral Medical Inc
[{"type":"text","content":"\n\n\n May 19, 2011 (Canada NewsWire Group) -- \n\n#ReleaseContent TABLE\n{\n BORDER-COLLAPSE: collapse\n}\nTR.cnwUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 1px solid\n}\nTR.cnwDoubleUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 3px double\n}\nTR.cnwBoldUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 3px solid\n}\nTD.cnwUnderlinedCell\n{\n BORDER-BOTTOM: #000000 1px solid\n}\nTD.cnwDoubleUnderlinedCell\n{\n BORDER-BOTTOM: #000000 3px double\n}\nTD.cnwBoldUnderlinedCell\n{\n BORDER-BOTTOM: #000000 3px solid\n}\n#ReleaseContent TABLE.cnwBorderedTable TD\n{\n BORDER-RIGHT: black 1px solid;\n PADDING-RIGHT: 2px;\n BORDER-TOP: black 1px solid;\n PADDING-LEFT: 2px;\n PADDING-BOTTOM: 2px;\n BORDER-LEFT: black 1px solid;\n PADDING-TOP: 2px;\n BORDER-BOTTOM: black 1px solid;\n BORDER-COLLAPSE: collapse\n}\n#ReleaseContent TABLE TD\n{\n PADDING-RIGHT: 2px;\n PADDING-LEFT: 2px;\n PADDING-BOTTOM: 2px;\n PADDING-TOP: 2px\n}\n\n\nTORONTO, May 19 /CNW/ - Spectral Diagnostics Inc., (TSX:SDI), a Phase III company developing the first theranostic treatment for\n septic shock, today announced that Dr. Paul Walker, the Company's\n President and Chief Executive Officer, will present at BioFinance 2011\n on Wednesday, June 1, at 10:15 a.m. Eastern Time. The conference will\n be held at the St. Andrew's Club & Conference Centre in Toronto,\n Ontario.\n\n\nDr. Walker will provide a corporate update, including information about\n the Company's pivotal sepsis program.\n\n\nBioFinance is a prominent Canadian investor conference for the life\n sciences industry. The two-day event brings together key industry\n players interested in investment opportunities and issues affecting\n companies in the life sciences sector. Presenting companies span a\n range of industries including biologics, medical devices, drug\n delivery, vaccines, and diagnostics.\n\n\nAbout Spectral Diagnostics\nSpectral is a Phase III company seeking U.S. FDA approval for its lead\n theranostics product for the treatment of patients with septic shock.\n Toraymyxin is a therapeutic hemoperfusion device that removes\n endotoxin, which can cause sepsis, from the bloodstream. Directed by\n the Company's Endotoxin Activity Assay (EAA™), the only FDA cleared\n diagnostic for the risk of developing sepsis, Spectral's EUPHRATES\n trial is the world's first theranostics trial in the area o...